Recombinant Pongo abelii Muscarinic acetylcholine receptor M1 (CHRM1)

What expression systems are optimal for producing recombinant Pongo abelii CHRM1, and how do researchers validate their functionality?

Recombinant CHRM1 production requires expression systems that preserve its structural integrity and post-translational modifications. Mammalian systems, such as Chinese Hamster Ovary (CHO) cells, are widely used due to their ability to perform complex glycosylation and folding . For example, the CHO-CHRM1 cell line expresses human CHRM1 via recombinase-mediated cassette exchange (RMCE), ensuring stable and controlled receptor production . Insect cell systems (e.g., Sf9) are alternatives but may lack mammalian-specific modifications.

Validation methodology:

• Radioligand binding assays using antagonists like pirenzepine (M1-selective) to confirm ligand-binding affinity.

• Functional assays measuring G-protein-coupled responses (e.g., cAMP inhibition or calcium mobilization via phospholipase C activation) .

• Immunoblotting with anti-CHRM1 antibodies to verify protein size (∼51 kDa) and glycosylation status .

How do researchers assess the purity and post-translational modifications of recombinant CHRM1?

Purity is critical for structural and functional studies. Size-exclusion chromatography (SEC) and SDS-PAGE are standard methods, with ≥95% purity required for crystallography . Post-translational modifications are analyzed via:

• Mass spectrometry to identify phosphorylation sites (e.g., Ser/Thr residues in the third intracellular loop) and glycosylation patterns.

• Enzymatic deglycosylation (e.g., PNGase F treatment) to distinguish N-linked glycans .

For example, the recombinant CHRM1 from Pongo abelii (UniProt Q5R949) contains a 460-amino-acid sequence with predicted glycosylation at Asn2 and Asn12 .

What in vitro assays are used to characterize CHRM1 signaling pathways?

Key assays include:

• Calcium imaging: CHRM1 activates Gq/11-coupled pathways, increasing intracellular Ca²⁺. Fluorescent dyes (e.g., Fluo-4) quantify responses to agonists like carbachol .

• cAMP inhibition assays: Co-transfection with cAMP biosensors (e.g., GloSensor) measures Gi/o-mediated suppression of adenylate cyclase .

• β-arrestin recruitment assays (e.g., BRET/FRET) to study biased signaling .

How do structural variations in CHRM1 between species impact translational research?

Pongo abelii CHRM1 shares 98% homology with human CHRM1 but differs at residues critical for ligand specificity (e.g., Leu112 in transmembrane domain 3) . Researchers address this by:

• Molecular dynamics simulations comparing ligand-binding pockets.

• Chimeric receptor studies swapping domains between species to isolate functional regions .

For example, bluegill M5 receptor studies revealed that non-mammalian models require careful extrapolation due to divergent signaling pathways .

What strategies resolve contradictory data in CHRM1-mediated gene expression studies?

Discrepancies arise from model system limitations (e.g., Chrm1−/− mice vs. human postmortem tissue). Solutions include:

• Cross-species transcriptomics: Compare cortical gene expression in Chrm1−/− mice with human schizophrenia datasets . Overlap in pathways like mitochondrial dysfunction (e.g., COX6A1 downregulation) strengthens validity .

• Dose-response analyses using partial agonists (e.g., xanomeline) to distinguish linear vs. biphasic signaling effects.

How is recombinant CHRM1 used to model neuropsychiatric disorders?

CHRM1 deficits are implicated in schizophrenia and Alzheimer’s disease . Advanced models include:

• Induced pluripotent stem cell (iPSC)-derived neurons: Edit CHRM1 expression via CRISPR/Cas9 and assay dendritic arborization deficits.

• Transgenic mice with conditional CHRM1 knockout in cortical pyramidal neurons to isolate cognitive phenotypes .

Table 1: Comparison of CHRM1 Expression Systems

Table 2: Key CHRM1 Signaling Assays

Data Contradiction Analysis Framework

• Identify confounding variables: In Chrm1−/− mice, compensatory upregulation of CHRM3 may mask cognitive deficits .

• Leverage multi-omics: Integrate RNA-seq data from knockout models with proteomics of postmortem tissue to filter false positives.

• Validate in human cells: Use iPSC-derived neurons treated with CHRM1-positive allosteric modulators (e.g., BQCA) to confirm conserved pathways .

Ethical and Technical Considerations

• Species-specific ethics: Pongo abelii is endangered; recombinant systems reduce reliance on native tissues .

• Signal transduction bias: Antibody validation is critical, as commercial anti-CHRM1 antibodies often cross-react with CHRM3 .